Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 46 entries
View as:

Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT06485752 Org: User:
Start: 11/30/24 End: 02/04/25 Due: 02/04/26

Lot Consistency Study of COVID-19 and Influenza Combination Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT06482359 Org: User:
Start: 02/01/25 End: 05/17/26 Due: 05/17/27

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

Phase: N/A Priority: Normal
NCT ID: NCT02266628 Org: User:
Start: 10/31/14 End: 03/31/16 Due: 03/31/17

A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults

Phase: N/A Priority: Normal
NCT ID: NCT04533399 Org: User:
Start: 08/17/20 End: 01/19/22 Due: 01/19/23

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Phase: N/A Priority: Normal
NCT ID: NCT05463068 Org: User:
Start: 07/11/22 End: 09/01/22 Due: 09/01/23

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

Phase: N/A Priority: Normal
NCT ID: NCT04368988 Org: User:
Start: 05/25/20 End: 06/01/22 Due: 06/01/23

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Phase: N/A Priority: Normal
NCT ID: NCT02307851 Org: User:
Start: 11/30/14 End: 06/30/15 Due: 06/30/16

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

Phase: N/A Priority: Normal
NCT ID: NCT04583995 Org: User:
Start: 09/28/20 End: 03/29/22 Due: 03/29/23

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Phase: N/A Priority: Normal
NCT ID: NCT04611802 Org: User:
Start: 12/27/20 End: 12/15/23 Due: 12/15/24

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Phase: N/A Priority: Normal
NCT ID: NCT05975060 Org: User:
Start: 09/07/23 End: 05/20/24 Due: 05/20/25

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

Phase: N/A Priority: Normal
NCT ID: NCT04120194 Org: User:
Start: 10/14/19 End: 12/13/20 Due: 12/13/21

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT05925127 Org: User:
Start: 10/16/23 End: 05/21/24 Due: 05/21/25

A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults

Phase: N/A Priority: Normal
NCT ID: NCT01561768 Org: User:
Start: 03/31/12 End: 01/31/13 Due: 01/31/14

Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT05973006 Org: User:
Start: 08/16/23 End: 09/30/24 Due: 09/30/25

Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT05875701 Org: User:
Start: 03/28/23 End: 11/11/23 Due: 11/11/24

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Phase: N/A Priority: Normal
NCT ID: NCT02247726 Org: User:
Start: 09/30/14 End: 07/31/16 Due: 07/31/17

RSV F Dose-Ranging Study in Women

Phase: N/A Priority: Normal
NCT ID: NCT01960686 Org: User:
Start: 10/31/13 End: 04/30/14 Due: 04/30/15

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT05519839 Org: User:
Start: 12/30/22 End: 12/24/23 Due: 12/24/24

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Phase: N/A Priority: Normal
NCT ID: NCT01709019 Org: User:
Start: 10/31/12 End: 03/31/14 Due: 03/31/15

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

Phase: N/A Priority: Normal
NCT ID: NCT01897701 Org: User:
Start: 07/31/13 End: 08/31/14 Due: 08/31/15

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

Phase: N/A Priority: Normal
NCT ID: NCT02078674 Org: User:
Start: 03/31/14 End: 07/31/15 Due: 07/31/16

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Phase: N/A Priority: Normal
NCT ID: NCT00519389 Org: User:
Start: 07/31/07 End: 11/30/08 Due: 11/30/09

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

Phase: N/A Priority: Normal
NCT ID: NCT03293498 Org: User:
Start: 09/18/17 End: 10/29/18 Due: 10/29/19

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT05372588 Org: User:
Start: 05/25/22 End: 04/07/24 Due: 04/07/25

RSV-F Vaccine Dose Ranging Study in Young Women

Phase: N/A Priority: Normal
NCT ID: NCT01704365 Org: User:
Start: 10/31/12 End: 05/31/13 Due: 05/31/14